CAPTRUST Financial Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

CAPTRUST Financial Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,660	Closed	-$27.1K	–	2625
2023 Q1	$27.1K	Buy	+14,660	New	+$18.2K	﹤0.01%	2238
2022 Q4	–	Sell	-35,599	Closed	-$83K	–	2247
2022 Q3	$83K	Buy	35,599 +13,099	+58%	+$46.4K	﹤0.01%	1956
2022 Q2	$68K	Sell	22,500 -2,000	-8%	-$9.73K	﹤0.01%	2514
2022 Q1	$166K	Hold	24,500	–	–	﹤0.01%	1860
2021 Q4	$205K	Hold	24,500	–	–	﹤0.01%	1624
2021 Q3	$182K	Hold	24,500	–	–	﹤0.01%	1630
2021 Q2	$167K	Buy	24,500 +3,000	+14%	+$24.9K	﹤0.01%	1644
2021 Q1	$221K	Buy	21,500 +10,000	+87%	+$110K	﹤0.01%	1412
2020 Q4	$80K	Buy	11,500 +500	+5%	+$3.89K	﹤0.01%	1610
2020 Q3	$99K	Hold	11,000	–	–	﹤0.01%	1345
2020 Q2	$73K	Buy	+11,000	New	+$59.3K	﹤0.01%	1477

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

CAPTRUST Financial Advisors's JNCE Position: Q2 2023 in Review

CAPTRUST Financial Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 14,660 shares — an estimated $27.1K sold.

CAPTRUST Financial Advisors first reported a position in JNCE in Q2 2020 and held it in 11 quarters. The position peaked at $221K in Q1 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

CAPTRUST Financial Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
CAPTRUST Financial Advisors sold 14,660 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $27.1K.
CAPTRUST Financial Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2020 and held it in 11 quarters.
CAPTRUST Financial Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $221K in Q1 2021.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2023, filed 15 Aug 2023.